Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: JARDIANCE 10mg
Drug: JARDIANCE 25mg

First Posted Date: 2016-07-29

Last Posted Date: 2021-05-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3368

Registration Number: NCT02848833

Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2016-07-21

Last Posted Date: 2019-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 671

Registration Number: NCT02839746

CU Programme of Idarucizumab for Japanese Patients

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Drug: idarucizumab

First Posted Date: 2016-07-13

Last Posted Date: 2018-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1

Registration Number: NCT02831660

Locations: 🇯🇵
Fukuoka Tokushukai Medical Center, Fukuoka, Kasuga, Japan

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: BI 425809 dose 1
Drug: BI 425809 dose 2
Drug: BI 425809 dose 4
Drug: BI 425809 dose 3
Drug: Placebo

First Posted Date: 2016-07-13

Last Posted Date: 2021-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 509

Registration Number: NCT02832037

Locations: 🇺🇸
North Carolina Psychiatric Research Center, Raleigh, North Carolina, United States
🇺🇸
Midwest Clinical Research, Dayton, Ohio, United States
🇬🇧
King's College Hospital, London, United Kingdom

and more 78 locations

Japanese IP-TN Trial

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Loxoprofen sodium
Drug: Methocarbamol

First Posted Date: 2016-07-13

Last Posted Date: 2018-07-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02831569

Locations: 🇯🇵
Shinjuku Res. Park Clinic, Tokyo, I.M., Tokyo, Shinjyuku-ku, Japan
🇯🇵
Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵
Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Drug: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
Drug: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Drug: 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

First Posted Date: 2016-07-04

Last Posted Date: 2020-03-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT02821910

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Empa/Lina FDC Food Effect Study (Japan)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: empagliflozin/linagliptin FDC

First Posted Date: 2016-06-28

Last Posted Date: 2018-08-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT02815644

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Drug: Idarucizumab

First Posted Date: 2016-06-28

Last Posted Date: 2020-04-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1

Registration Number: NCT02815670

Locations: 🇷🇺
Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan, Kazan, Russian Federation
🇷🇺
Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept, Tyumen, Russian Federation

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Completed

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2016-06-17

Last Posted Date: 2019-09-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 209

Registration Number: NCT02803580

Locations: 🇮🇹
Osp. S. Giuseppe Fatebenefratelli, Milano, Italy
🇮🇹
Azienda Ospedaliera Policlinico di Modena, Modena, Italy
🇮🇹
Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli, Forli, Italy

and more 15 locations

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2016-06-16

Last Posted Date: 2019-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT02802345

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
🇫🇷
HOP Bichat, Paris, France
🇮🇳
Care Institute Of Medical Sciences, Ahmedabad, India

and more 82 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy